Jennifer Le‐Rademacher

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Bart L. Scott, Marcelo C. Pasquini, Brent R. Logan et al. · Journal of Clinical Oncology · 2017 · 649 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Optimal Regimen Intensity +16

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

Robert D. McBane, Waldemar E. Wysokiński, Jennifer Le‐Rademacher et al. · Journal of Thrombosis and Haemostasis · 2019 · 554 citations

Thrombosis, Venous Thrombosis, Adam Vte Trial +6

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Wei Ding, Betsy LaPlant, Timothy G. Call et al. · Blood · 2017 · 411 citations · Full text

Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

Robert J. Soiffer, Jennifer Le‐Rademacher, Vincent T. Ho et al. · Blood · 2011 · 350 citations · Full text

Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma

Sonali M. Smith, Linda J. Burns, Koen van Besien et al. · Journal of Clinical Oncology · 2013 · 229 citations · Full text